Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,616,785
Closed -$23.8M 6540
2025
Q3
$23.8M Buy
1,616,785
+363,700
+29% +$3.71M ﹤0.01% 2101
2025
Q2
$12.3M Buy
1,253,085
+257,636
+26% +$2.13M ﹤0.01% 2573
2025
Q1
$7.24M Buy
995,449
+188,367
+23% +$1.65M ﹤0.01% 2994
2024
Q4
$6.31M Buy
807,082
+73,585
+10% +$606K ﹤0.01% 3212
2024
Q3
$5.43M Sell
733,497
-171,320
-19% -$1.44M ﹤0.01% 3271
2024
Q2
$7.25M Buy
904,817
+159,869
+21% +$1.43M ﹤0.01% 2819
2024
Q1
$8.67M Buy
744,948
+113,836
+18% +$1.26M ﹤0.01% 2598
2023
Q4
$7.05M Buy
631,112
+112,438
+22% +$1.03M ﹤0.01% 2844
2023
Q3
$8.01M Sell
518,674
-96,493
-16% -$1.62M ﹤0.01% 2582
2023
Q2
$11.7M Buy
615,167
+146,976
+31% +$2.58M ﹤0.01% 2306
2023
Q1
$7.13M Sell
468,191
-191,733
-29% -$2.5M ﹤0.01% 2722
2022
Q4
$8.4M Buy
659,924
+271,344
+70% +$2.44M ﹤0.01% 2730
2022
Q3
$2.25M Buy
388,580
+302,519
+352% +$1.33M ﹤0.01% 3882
2022
Q2
$277K Buy
86,061
+16,025
+23% +$48.4K ﹤0.01% 5472
2022
Q1
$264K Buy
70,036
+59,791
+584% +$385K ﹤0.01% 5731
2021
Q4
$134K Buy
+10,245
New +$162K ﹤0.01% 6040
2021
Q3
Sell
-12,525
Closed -$234K 6306
2021
Q2
$234K Sell
12,525
-12,106
-49% -$270K ﹤0.01% 5667
2021
Q1
$583K Buy
24,631
+15,536
+171% +$359K ﹤0.01% 5005
2020
Q4
$222K Buy
+9,095
New +$233K ﹤0.01% 5041
2020
Q1
Sell
-22,836
Closed -$600K 5295
2019
Q4
$600K Buy
+22,836
New +$635K ﹤0.01% 4400

Other funds holding ETNB

Goldman Sachs's ETNB Position: Q4 2025 in Review

Goldman Sachs sold out of 89bio (ETNB) in Q4 2025, closing a stake of 1,616,785 shares — an estimated $23.8M sold.

Goldman Sachs first reported a position in ETNB in Q4 2019 and held it in 20 quarters. The position peaked at $23.8M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • Goldman Sachs reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,616,785 89bio shares in Q4 2025, an estimated $23.8M.
  • Goldman Sachs first reported a position in 89bio in Q4 2019 and held it in 20 quarters.
  • Goldman Sachs's 89bio position peaked at $23.8M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.